Radioprotectors and mitigators of radiation-induced normal tissue injury

Oncologist

Volumn 15, Issue 4, 2010, Pages 360-371

  Citrin, Deborah ^a   Cotrim, Ana P ^b   Hyodo, Fuminori ^a   Baum, Bruce J ^b   Krishna, Murali C ^a   Mitchell, James B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Amifostine; Mitigators; Radioprotector; Tempol

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMIFOSTINE; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BOWMAN BIRK PROTEINASE INHIBITOR; CAPTOPRIL; CBLB 502; DIETHYLDITHIOCARBAMIC ACID; ENALAPRIL; GENISTEIN; GLUTATHIONE; MELATONIN; MELATONIN DERIVATIVE; MISCELLANEOUS DRUGS AND AGENTS; NITROXIDE; OLTIPRAZ; PALIFERMIN; POLYPEPTIDE; PRAVASTATIN; PROTEINASE INHIBITOR; RADIATION MITIGATOR; RADIOPROTECTIVE AGENT; RAMIPRIL; RETINOL; SIMVASTATIN; TEMPOL; THIOCTIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE TOXICITY; ALOPECIA; ARTICLE; CANCER RADIOTHERAPY; CHRONIC TOXICITY; CLINICAL TRIAL; CYSTITIS; DRUG APPROVAL; DRUG MEGADOSE; DRUG USE; DYSPHAGIA; EVENING DOSAGE; HUMAN; KIDNEY DISEASE; LUNG FIBROSIS; MORNING DOSAGE; MUCOSA INFLAMMATION; NONHUMAN; OPTIC NERVE DISEASE; PRIORITY JOURNAL; PROCTITIS; QUALITY OF LIFE; RADIATION DERMATITIS; RADIATION ENTEROPATHY; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PNEUMONIA; RADIATION PROTECTION; RECTUM INJURY; SYMPTOM; TISSUE INJURY; XEROSTOMIA;

AMIFOSTINE; ANIMALS; ANTIOXIDANTS; CYCLIC N-OXIDES; DNA DAMAGE; FIBROBLAST GROWTH FACTOR 7; FREE RADICAL SCAVENGERS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; RADIATION INJURIES; RADIATION PROTECTION; RADIATION-PROTECTIVE AGENTS; RISK FACTORS; SPIN LABELS;

EID: 77951724979     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-S104     Document Type: Article

References (92)

1. Ringborg U, Bergqvist D, Brorsson B et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001-summary and conclusions. Acta Oncol 2003;42:357-365.
2. Stone HB, Moulder JE, Coleman CN et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res 2004;162: 711-728.
3. Hall EJ, Giaccia AJ. Radiobiology for the Radiologist, Sixth Edition. Philadelphia: Lippincott Williams & Wilkins, 2006:5-15.
4. von Sonntag C. The Chemical Basis of Radiation Biology. London: Taylor & Francis, 1987:31-56.
5. Xavier S, Yamada K, Samuni AM et al. Differential protection by nitroxides and hydroxylamines to radiation-induced and metal ion-catalyzed oxidative damage. Biochim Biophys Acta 2002;1573:109-120.
6. Patt HM, Tyree EB, Straube RL et al. Cysteine protection against X irradiation. Science 1949;110:213-214.
7. Bacq ZM. The amines and particularly cysteamine as protectors against roentgen rays. Acta Radiol 1954;41:47-55.
8. Landauer MR, Davis HD, Dominitz JA et al. Comparative behavioral toxicity of four sulfhydryl radioprotective compounds in mice: WR-2721, cysteamine, diethyldithiocarbamate, and N-acetylcysteine. Pharmacol Ther 1988;39:97-100.
9. Calabro-Jones PM, Fahey RC, Smoluk GD et al. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol Relat Stud Phys Chem Med 1985;47:23-27.
10. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphos-phorothioic acid. Cancer Res 1980;40:1519-1524.
11. Purdie JW, Inhaber ER, Schneider H et al. Interaction of cultured mammalian cells with WR-2721 and its thiol, WR-1065: Implications for mechanisms of radioprotection. Int J Radiat Biol Relat Stud Phys Chem Med 1983;43:517-527.
12. Glover D, Negendank W, Delivoria-Papadopoulos M et al. Alterations in oxygen transport following WR-2721. Int J Radiat Oncol Biol Phys 1984; 10:1565-1568.
13. Savoye C, Swenberg C, Hugot S et al. Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage. Int J Radiat Biol 1997;71:193-202.
14. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: The first selective-target and broad-spectrum radioprotector. The Oncologist 2007;12:738-747.
15. Schuchter LM, Hensley ML, Meropol NJ et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20:2895-2903.
16. Hensley ML, Hagerty KL, Kewalramani T et al. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27:127-145.
17. Brizel DM, Overgaard J. Does amifostine have a role in chemoradiation treatment? Lancet Oncol 2003;4:378-381.
18. Soule BP, Hyodo F, Matsumoto K et al. Therapeutic and clinical applications of nitroxide compounds. Antioxid Redox Signal 2007;9:1731-1743.
19. Mitchell JB, DeGraff W, Kaufman D et al. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch Biochem Biophys 1991;289:62-70.
20. Hahn SM, Tochner Z, Krishna CM et al. Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res 1992;52:1750-1753.
21. Cuscela D, Coffin D, Lupton GP et al. Protection from radiation-induced alopecia with topical application of nitroxides: Fractionated studies. Cancer J Sci Am 1996;2:273-278.
22. Goffman T, Cuscela D, Glass J et al. Topical application of nitroxide protects radiation-induced alopecia in guinea pigs. Int J Radiat Oncol Biol Phys 1992;22:803-806.
23. Metz JM, Smith D, Mick R et al. A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy. Clin Cancer Res 2004;10:6411-6417.
24. Cotrim AP, Hyodo F, Matsumoto K et al. Differential radiation protection of salivary glands versus tumor by Tempol with accompanying tissue assessment of Tempol by magnetic resonance imaging. Clin Cancer Res 2007;13:4928-4933.
25. Matsumoto K, Hyodo F, Matsumoto A et al. High-resolution mapping of tumor redox status by magnetic resonance imaging using nitroxides as redox-sensitive contrast agents. Clin Cancer Res 2006;12:2455-2462.
26. Hyodo F, Matsumoto K, Matsumoto A et al. Probing the intracellular redox status of tumors with magnetic resonance imaging and redox-sensitive contrast agents. Cancer Res 2006;66:9921-9928.
27. Chitra S, Shyamala Devi CS. Effects of radiation and alpha-tocopherol on saliva flow rate, amylase activity, total protein and electrolyte levels in oral cavity cancer. Indian J Dent Res 2008;19:213-218.
28. Bairati I, Meyer F, Gélinas M et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol 2005;23:5805-5813.
29. Ferreira PR, Fleck JF, Diehl A et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: A double-blind randomized trial. Head Neck 2004;26:313-321.
30. Misirlioglu CH, Demirkasimoglu T, Kucukplakci B et al. Pentoxifylline and alpha-tocopherol in prevention of radiation-induced lung toxicity in patients with lung cancer. Med Oncol 2007;24:308-311.
31. Sanchiz F, Milla A, Artola N et al. Prevention of radioinduced cystitis by orgotein: A randomized study. Anticancer Res 1996;16:2025-2028.
32. Halperin EC, Gaspar L, George S et al. A double-blind, randomized, prospective trial to evaluate topical vitamin C solution for the prevention of radiation dermatitis. CNS Cancer Consortium. Int J Radiat Oncol Biol Phys 1993;26:413-416.
33. Camphausen K, Citrin D, Krishna MC et al. Implications for tumor control during protection of normal tissues with antioxidants. J Clin Oncol 2005; 23:5455-5457.
34. Meyer F, Bairati I, Fortin A et al. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: A randomized trial among head and neck cancer patients. Int J Cancer 2008;122:1679-1683.
35. Guo H, Seixas-Silva JA Jr, Epperly MW et al. Prevention of radiation-induced oral cavity mucositis by plasmid/liposome delivery of the human manganese superoxide dismutase (SOD2) transgene. Radiat Res 2003;159: 361-370.
36. Stickle RL, Epperly MW, Klein E et al. Prevention of irradiation-induced esophagitis by plasmid/liposome delivery of the human manganese superoxide dismutase transgene. Radiat Oncol Investig 1999;7:204-217.
37. Epperly MW, Bray JA, Krager S et al. Intratracheal injection of adenovirus containing the human MnSOD transgene protects athymic nude mice from irradiation-induced organizing alveolitis. Int J Radiat Oncol Biol Phys 1999;43:169-181.
38. Epperly MW, Travis EL, Sikora C et al. Manganese [correction of Magnesium] superoxide dismutase (MnSOD) plasmid/liposome pulmonary radio-protective gene therapy: Modulation of irradiation-induced mRNA for IL-I, TNF-alpha, and TGF-beta correlates with delay of organizing alveolitis/ fibrosis. Biol Blood Marrow Transplant 1999;5:204-214.
39. Epperly MW, Defilippi S, Sikora C et al. Intratracheal injection of manganese superoxide dismutase (MnSOD) plasmid/liposomes protects normal lung but not orthotopic tumors from irradiation. Gene Ther 2000;7:1011-1018.
40. Delanian S, Baillet F, Huart J et al. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: Clinical trial. Radiother Oncol 1994;32:12-20.
41. Lefaix JL, Delanian S, Leplat JJ et al. Successful treatment of radiation-induced fibrosis using Cu/Zn-SOD and Mn-SOD: An experimental study. Int J Radiat Oncol Biol Phys 1996;35:305-312.
42. Urano M, Kuroda M, Reynolds R et al. Expression of manganese superoxide dismutase reduces tumor control radiation dose: Gene-radiotherapy. Cancer Res 1995;55:2490-2493.
43. Reiter RJ, Tan DX, Burkhardt S. Reactive oxygen and nitrogen species and cellular and organismal decline: Amelioration with melatonin. Mech Ageing Dev 2002;123:1007-1019.
44. Reiter RJ, Tan DX, Manchester LC et al. Melatonin: Detoxification of oxygen and nitrogen-based toxic reactants. Adv Exp Med Biol 2003;527: 539-548.
45. Lopez-Burillo S, Tan DX, Mayo JC et al. Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and alpha-lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: A study of their individual and synergistic actions. J Pineal Res 2003;34:269-277.
46. Kaya H, Delibas N, Serteser M et al. The effect of melatonin on lipid peroxidation during radiotherapy in female rats. Strahlenther Onkol 1999;175: 285-288.
47. Okatani Y, Wakatsuki A, Shinohara K et al. Melatonin stimulates glutathione peroxidase activity in human chorion. J Pineal Res 2001;30:199-205.
48. Blickenstaff RT, Brandstadter SM, Reddy S et al. Potential radioprotective agents. 1. Homologs of melatonin. J Pharm Sci 1994;83:216-218.
49. Vijayalaxmi, Meltz ML, Reiter RJ et al. Melatonin and protection from whole-body irradiation: Survival studies in mice. Mutat Res 1999;425: 21-27.
50. Topkan E, Tufan H, Yavuz AA et al. Comparison of the protective effects of melatonin and amifostine on radiation-induced epiphyseal injury. Int J Radiat Biol 2008;84:796-802.
51. Manda K, Ueno M, Anzai K. Cranial irradiation-induced inhibition of neurogenesis in hippocampal dentate gyrus of adult mice: Attenuation by melatonin pretreatment. J Pineal Res 2009;46:71-78.
52. Hussein MR, Abu-Dief EE, Kamel E et al. Melatonin and roentgen irradiation-induced acute radiation enteritis in Albino rats: An animal model. Cell Biol Int 2008;32:1353-1361.
53. Manda K, Anzai K, Kumari S et al. Melatonin attenuates radiation-induced learning deficit and brain oxidative stress in mice. Acta Neurobiol Exp (Wars) 2007;67:63-70.
54. Akagi T, Ushinohama K, Ikesue S et al. Chronopharmacology of melatonin in mice to maximize the antitumor effect and minimize the rhythm disturbance effect. J Pharmacol Exp Ther 2004;308:378-384.
55. Blask DE, Barthold HJ, Dauchy RT et al. Melatonin radiosensitizes tumors and radioprotects normal tissues: Time-of day dependency. Am Assoc Cancer Res 2000.; Abstract 338.
56. Berk L, Berkey B, Rich T et al. Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int J Radiat Oncol Biol Phys 2007;68:852-857.
57. Burdelya LG, Krivokrysenko VI, Tallant TC et al. An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008;320:226-230.
58. Uematsu S, Jang MH, Chevrier N et al. Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c lamina propria cells. Nat Immunol 2006;7:868-874.
59. Maaser C, Heidemann J, von Eiff C et al. Human intestinal microvascular endothelial cells express Toll-like receptor 5: A binding partner for bacterial flagellin. J Immunol 2004;172:5056-5062.
60. Wang Y, Meng A, Lang H et al. Activation of nuclear factor kappaB in vivo selectively protects the murine small intestine against ionizing radiation-induced damage. Cancer Res 2004;64:6240-6246.
61. Bentzen SM. Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat Rev Cancer 2006;6:702-713.
62. ClinicalTrials.gov. Vol 2008. Accessed January 12, 2009.
63. Dittmann KH, Gueven N, Mayer C et al. The radioprotective effect of BBI is associated with the activation of DNA repair-relevant genes. Int J Radiat Biol 1998;74:225-230.
64. Dittmann K, Virsik-Köpp P, Mayer C et al. Bowman-Birk protease inhibitor activates DNA-dependent protein kinase and reduces formation of radiation-induced dicentric chromosomes. Int J Radiat Biol 2003;79:801-808.
65. Dittmann K, Mayer C, Kehlbach R et al. The radioprotector Bowman-Birk proteinase inhibitor stimulates DNA repair via epidermal growth factor receptor phosphorylation and nuclear transport. Radiother Oncol 2008;86: 375-382.
66. Kennedy AR, Davis JG, Carlton W et al. Effects of dietary antioxidant supplementation on the development of malignant lymphoma and other neoplastic lesions in mice exposed to proton or iron-ion radiation. Radiat Res 2008;169:615-625.
67. Dittmann K, Toulany M, Classen J et al. Selective radioprotection of normal tissues by Bowman-Birk proteinase inhibitor (BBI) in mice. Strahlenther Onkol 2005;181:191-196.
68. Kim SG, Nam SY, Kim CW. In vivo radioprotective effects of oltipraz in gamma-irradiated mice. Biochem Pharmacol 1998;55:1585-1590.
69. Moulder JE, Cohen EP. Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin Radiat Oncol 2007; 17:141-148.
70. Moulder JE, Fish BL, Cohen EP et al. Angiotensin II receptor antagonists in the prevention of radiation nephropathy. Radiat Res 1996;146:106-110.
71. Kim JH, Brown SL, Kolozsvary A et al. Modification of radiation injury by ramipril, inhibitor of angiotensin-converting enzyme, on optic neuropathy in the rat. Radiat Res 2004;161:137-142.
72. Ward WF, Molteni A, Ts'ao CH et al. Radiation pneumotoxicity in rats: Modification by inhibitors of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys 1992;22:623-625.
73. Yousefi S, Green DR, Blaser K et al. Protein-tyrosine phosphorylation regulates apoptosis in human eosinophils and neutrophils. Proc Natl Acad Sci USA 1994;91:10868-10872.
74. Landauer MR, Srinivasan V, Seed TM. Genistein treatment protects mice from ionizing radiation injury. J Appl Toxicol 2003;23:379-385.
75. Haydont V, Bourgier C, Pocard M et al. Pravastatin inhibits the Rho/CCN2/ extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin Cancer Res 2007;13:5331-5340.
76. Wang J, Boerma M, Fu Q et al. Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. Int J Radiat Oncol Biol Phys 2007;68:1483-1490.
77. Williams JP, Hernady E, Johnston CJ et al. Effect of administration of lovastatin on the development of late pulmonary effects after whole-lung irradiation in a murine model. Radiat Res 2004;161:560-567.
78. Finch PW, Rubin JS. Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv Cancer Res 2004;91:69-136.
79. Lombaert IM, Brunsting JF, Wierenga PK et al. Keratinocyte growth factor prevents radiation damage to salivary glands by expansion of the stem/ progenitor pool. STEM CELLS 2008;26:2595-2601.
80. Yeoh A, Gibson R, Yeoh E et al. Radiation therapy-induced mucositis: Relationships between fractionated radiation, NF-kappaB, COX-1, and COX-2. Cancer Treat Rev 2006;32:645-651.
81. Sminia P, Kuipers G, Geldof A et al. COX-2 inhibitors act as radiosensitizer in tumor treatment. Biomed Pharmacother 2005;59(suppl 2):S272-S275.
82. Guadagni F, Ferroni P, Palmirotta R et al. Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. Anticancer Res 2007;27:3147-3162.
83. Bertho JM, Frick J, Prat M et al. Comparison of autologous cell therapy and granulocyte-colony stimulating factor (G-CSF) injection vs. G-CSF injection alone for the treatment of acute radiation syndrome in a non-human primate model. Int J Radiat Oncol Biol Phys 2005;63:911-920.
84. Uckun FM, Souza L, Waddick KG et al. In vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice. Blood 1990;75:638-645.
85. Farrell CL, Rex KL, Kaufman SA et al. Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol 1999;75:609-620.
86. Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-2598.
87. Brizel DM, Murphy BA, Rosenthal DI et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2008;26:2489-2496.
88. Anscher MS, Thrasher B, Zgonjanin L et al. Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2008;71:829-837.
89. Anscher MS, Thrasher B, Rabbani Z et al. Antitransforming growth factor-beta antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation. Int J Radiat Oncol Biol Phys 2006;65:876-881.
90. Xavier S, Piek E, Fujii M et al. Amelioration of radiation-induced fibrosis: Inhibition of transforming growth factor-beta signaling by halofuginone. J Biol Chem 2004;279:15167-15176.
91. Massagué J. TGF in cancer. Cell 2008;134:215-230.
92. Baum BJ, Zheng C, Cotrim AP et al. Transfer of the AQP1 cDNA for the correction of radiation-induced salivary hypofunction. Biochim Biophys Acta 2006;1758:1071-1077.